Lupin receives approval from USFDA for Darunavir Tablets
The product will be manufactured at Lupin's facility in Nagpur, India.
The product will be manufactured at Lupin's facility in Nagpur, India.
The inspection concluded with no observation (FDA-483) issued.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Construction is now underway with the facility scheduled to be operational by 2025
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
The inspection of the facility was conducted from August 16-19, 2022.
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
Subscribe To Our Newsletter & Stay Updated